Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eone Diagnomics Genome Center Co., Ltd. (245620:KRX), powered by AI.
Eone Diagnomics Genome Center Co., Ltd. is currently trading at ₩415. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Eone Diagnomics Genome Center Co., Ltd. on Alpha Lenz.
Eone Diagnomics Genome Center Co., Ltd.'s P/E ratio is 5.3.
“Eone Diagnomics Genome Center Co., Ltd. trades at a P/E of 5.3 (undervalued) with modest ROE of -297.1%.”
Ask for details →Eone Diagnomics Genome Center Co., Ltd. is a biotechnology company specializing in the genomic analysis field. Its primary focus is on providing advanced genomic services and developing innovative diagnostic solutions, leveraging cutting-edge technologies in genetic sequencing and personalized medicine. The company is instrumental in impacting healthcare and research sectors by offering comprehensive genomic data analyses that aid in the early detection, treatment, and management of diseases. Eone Diagnomics Genome Center serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies, facilitating more precise and customized medical interventions. With the growing emphasis on precision medicine, the company plays a significant role in enhancing healthcare outcomes through its state-of-the-art genomic solutions. By continually expanding its capabilities and collaborations, Eone Diagnomics Genome Center contributes to advancing the understanding of the human genome and its application to improve health.
“Eone Diagnomics Genome Center Co., Ltd. trades at a P/E of 5.3 (undervalued) with modest ROE of -297.1%.”
Ask for details →Eone Diagnomics Genome Center Co., Ltd. (ticker: 245620) is a company listed on KRX in the Healthcare sector (Medical Distribution). It has approximately 103 employees. Market cap is $150.7B.
The current price is ₩415 with a P/E ratio of 5.34x and P/B of -6.69x.
ROE is -297.12% and operating margin is -20.25%. Annual revenue is $7.9B.